How Biotechs Are Using Cell Painting to Profile Drugs

Episode 37 of Biotech Business with Fexingo dives into cell painting — a high-content imaging technique that biotech startups are using to profile drug mechanisms, predict toxicity, and accelerate hit-to-lead decisions. Lucas explains how automated microscopy and machine learning turn thousands of cellular images into a 'morphological fingerprint' for each compound. Luna asks about scalability and how startups compete with big pharma's legacy assays. The episode walks through a concrete example: Recursion Pharmaceuticals, which uses cell painting at industrial scale, and how a new startup called Syzgy Bio is applying the method to phenotypic screens for rare diseases. Lucas closes with a forward-looking question about whether cell painting could replace traditional target-based screens. #CellPainting #DrugDiscovery #BiotechStartups #HighContentImaging #MorphologicalProfiling #PhenotypicScreen #MachineLearning #RecursionPharmaceuticals #SyzgyBio #HitToLead #DrugToxicity #LifeSciences #LabAutomation #Business #Technology #FexingoBusiness #BiotechPodcast #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo